At what enterprise value was APOLLO HEALTHCARE CORP. acquired in 2022?

During the acquisition of APOLLO HEALTHCARE CORP. by ANJAC BEAUTY & HEALTH in 2022, the transaction's Enterprise Value is estimated to be in the range of 100M - 350M EUR.

What was the revenue of APOLLO HEALTHCARE CORP. at the time of the deal?

The revenue of APOLLO HEALTHCARE CORP. at the time of the deal is estimated to be in the range of 100M - 200M EUR.

How is the data for the APOLLO HEALTHCARE CORP. acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the APOLLO HEALTHCARE CORP. deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.anjac.com/en/newsroom-anjac-acquires-apollo/

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.3x.

← DATABASE

Home Database Healthcare & PharmaAPOLLO HEALTHCARE CORP.

01/2022

APOLLO HEALTHCARE CORP. acquired by ANJAC BEAUTY & HEALTH

CANADA Life Sciences / Pharma & Biotech / CDMO EV 100M - 350M EUR

Context

Anjac acquired a majority stake in Apollo Healthcare Corp marking its 8th acquisition in five years. The founders, the Wachsberg brothers, remain as co-CEOs and shareholders. This deal is the cornerstone of Anjac's North American expansion, following the 2019 acquisition of Cosmetix West. The merger allows Anjac to offer global industrial capacity and specific OTC technologies (like FDA-approved sun care) to its international brand customers.

APOLLO HEALTHCARE CORP., which reported an EBITDA margin of in 2021, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Apollo Healthcare Corp. is one of North America's largest private label personal care manufacturers. It specializes in the development and high-volume production of beauty, wellness, and Over-The-Counter (OTC) products (notably sun care). Apollo serves major North American mass retailers, drugstores, and wholesale clubs. The company is known for its Corporate robustness and its ability to manage large-scale private label contracts for retail giants.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2021

2020

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
03/2022	FRESENIUS	IVENIX	UNITED STATES	Diagnostic Equipment
02/2022	MONTAGU PRIVATE EQUITY / PARTNERS GROUP	HTL BIOTECHNOLOGY	FRANCE	CDMO
01/2022	ARDIAN	BIOFARMA GROUP	ITALY	CDMO
01/2022	PERMIRA	BIO PRODUCTS LABORATORY (BPL)	UNITED KINGDOM	CDMO
01/2022	PERMIRA	KEDRION	ITALY	CDMO
12/2021	INTEGER	OSCOR	UNITED STATES	Implants & Prosthetics
12/2021	WINNCARE	PHARMAOUEST INDUSTRIES	FRANCE	Medical Devices
12/2021	THE CARLYLE GROUP / GTCR	RESONETICS	UNITED STATES	Medical Devices
12/2021	PLANMECA GROUP	KAVO DENTAL	GERMANY	Medical Devices
11/2021	COLOPLAST	ATOS MEDICAL	SWEDEN	Medical Consumables

REFERENCES

Valuation range: EV 100M - 350M EUR

Revenue range: 100M - 200M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of APOLLO HEALTHCARE CORP. by ANJAC BEAUTY & HEALTH are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.